Hyaluronic acid/Chitosan nanoparticles as delivery vehicles for VEGF and PDGF-BB
- PMID: 20883178
- DOI: 10.3109/10717544.2010.509357
Hyaluronic acid/Chitosan nanoparticles as delivery vehicles for VEGF and PDGF-BB
Abstract
The development of a vascular network in tissue-engineered constructs is a fundamental bottleneck of bioregenerative medicine, particularly when the size of the implant exceeds a certain limit given by diffusion lengths and/or if the host tissue shows a very active metabolism. One of the approaches to achieve the vascularization of tissue constructs is generating a sustained release of proangiogenic factors from the ischemic site. This work describes the formation and characterization of hyaluronic acid-chitosan (HA/CS) nanoparticles for the delivery of two pro-angiogenic growth factors: vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF-BB). These nanoparticles were prepared by an ionic gelification technique, and different formulations were developed by encapsulating the growth factors in association with two stabilizing agents: bovine serum albumin or heparin sodium salt. These carriers were characterized with regard to their physicochemical properties, their stability in biological media, and their cytotoxicity in the C3a hepatoma cell line. The results show that nanoparticles around 200 nm can be prepared by this method. HA/CS nanoparticles were stable when incubated in EMEM cell culture medium or in water at 37°C for 24 h. Cell culture tests confirmed that HA/CS nanoparticles are not cytotoxic within the concentration range used for growth factor delivery. Moreover, HA/CS nanoparticles were able to entrap efficiently both growth factors, reaching association values of 94% and 54% for VEGF and PDGF, respectively. In vitro release studies confirm that PDGF-BB is released from HA/CS nanoparticles in a sustained manner over approximately 1 week. On the other hand, VEGF is completely released within the first 24 h.
Similar articles
-
Nanoparticles based on PLGA:poloxamer blends for the delivery of proangiogenic growth factors.Mol Pharm. 2010 Oct 4;7(5):1724-33. doi: 10.1021/mp1001262. Epub 2010 Aug 12. Mol Pharm. 2010. PMID: 20681555
-
Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction.Cardiovasc Res. 2007 Jul 1;75(1):178-85. doi: 10.1016/j.cardiores.2007.03.028. Epub 2007 Apr 6. Cardiovasc Res. 2007. PMID: 17481597
-
Chitosan-hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma.Int J Pharm. 2009 Nov 3;381(2):122-9. doi: 10.1016/j.ijpharm.2009.04.009. Epub 2009 Apr 15. Int J Pharm. 2009. PMID: 19467809
-
Split for the cure: VEGF, PDGF-BB and intussusception in therapeutic angiogenesis.Biochem Soc Trans. 2014 Dec;42(6):1637-42. doi: 10.1042/BST20140234. Biochem Soc Trans. 2014. PMID: 25399582 Review.
-
Biomacromolecules as carriers in drug delivery and tissue engineering.Acta Pharm Sin B. 2018 Jan;8(1):34-50. doi: 10.1016/j.apsb.2017.11.005. Epub 2017 Dec 9. Acta Pharm Sin B. 2018. PMID: 29872621 Free PMC article. Review.
Cited by
-
Vascular endothelial growth factor-delivery systems for cardiac repair: an overview.Theranostics. 2012;2(6):541-52. doi: 10.7150/thno.3682. Epub 2012 Jun 4. Theranostics. 2012. PMID: 22737191 Free PMC article.
-
Concepts for Developing Physical Gels of Chitosan and of Chitosan Derivatives.Gels. 2018 Aug 9;4(3):67. doi: 10.3390/gels4030067. Gels. 2018. PMID: 30674843 Free PMC article. Review.
-
Angiogenic therapy for cardiac repair based on protein delivery systems.Heart Fail Rev. 2012 May;17(3):449-73. doi: 10.1007/s10741-011-9285-8. Heart Fail Rev. 2012. PMID: 21979836 Review.
-
Growth Factor and Cytokine Delivery Systems for Wound Healing.Cold Spring Harb Perspect Biol. 2022 Aug 1;14(8):a041234. doi: 10.1101/cshperspect.a041234. Cold Spring Harb Perspect Biol. 2022. PMID: 35667794 Free PMC article. Review.
-
The Microfluidic Technique and the Manufacturing of Polysaccharide Nanoparticles.Pharmaceutics. 2018 Dec 9;10(4):267. doi: 10.3390/pharmaceutics10040267. Pharmaceutics. 2018. PMID: 30544868 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources